UK companies driving cell and gene therapy: Rinri Therapeutics case study


Rinri Therapeutics is a spin-out from the University of Sheffield, developing a first-in-class cell therapy for hearing loss, the most common sensory deficit in humans. Targeting sensorineural hearing loss; those patients with damage to specialised cells of the inner ear. The latest BIA's UK cell and gene therapy report, explores the usage of Rinri Therapeutics' hematopoietic regenerative cell therapies for hearing loss.

What does the company do? 

Rinri Therapeutics is a biotechnology company based in Sheffield that is pioneering the development of regenerative cell therapies for hearing loss. The company’s innovative approach involves utilising auditory progenitor cells to replace the damaged auditory sensory cells in the inner ear, the primary structures responsible for converting sound waves into electrical signals that the brain can interpret.

How will it be used?

Rinri Therapeutics’ lead product is focused on the regeneration of Auditory neurons. These are specialised cells that transmit sound information from the inner ear (cochlea) to the auditory cortex in the brain. These cells are crucial for normal hearing; their damage or loss leads to hearing loss and degradation. Auditory nerve loss is common in acquired age-related hearing loss (presbycusis) and auditory neuropathy spectrum disorder (ANSD) (>11 million in high-income countries alone).

Rinri Therapeutics stands out as a frontrunner in this field, having conducted extensive preclinical studies demonstrating the potential of their regenerative cell therapy to restore hearing in animal models of auditory nerve-related hearing loss. The company’s differentiation technology enables the efficient and scalable conversion of pluripotent stem cells into auditory neurons, offering a promising avenue for treating hearing loss.

What is the impact?

Hearing loss is a prevalent global health concern, affecting an estimated 5% of the world’s  population (>400 million). The patient population will only increase, as the global population grows and ages. As there are no disease-modifying therapeutics for hearing loss, Rinri Therapeutics’ regenerative cell therapy has the potential to revolutionise the treatment of hearing loss. By effectively replacing damaged sensory cells in the inner ear, the therapy could restore hearing to millions of individuals who are currently suffering from hearing impairment. Disabling hearing loss (>35 dB loss) costs the EU €185 billion a year from increased health system expenditure, loss of productivity caused by unemployment and premature retirement, societal costs – social isolation, communication difficulties and stigma – and costs of additional educational support for children. Depression, loneliness, and social isolation are recognised as major consequences of hearing loss with multiple adverse effects on personal and family relationships.

As well as reducing quality of life, it is known that these conditions increase the likelihood of death in the elderly population. Hearing loss also has a detrimental effect on physical health as it increases the risk of onset of other diseases and is associated with a range of comorbidities (cognitive decline/dementia, depression, frequent falls). It has a negative impact on overall health-related quality of life, more than other chronic conditions (such as diabetes, hypertension, angina, sciatica, and congestive heart failure). This has important consequences for the social and practical care needed to support people with hearing impairment, therefore having an impact on wider society. 

Rinri degenrative therapy.png

What are the opportunities and challenges?

Developing and bringing a first-in-class stem cell-derived regenerative therapy to market requires de novo navigation of complex regulatory pathways and demonstrating the safety and efficacy of the treatment. Another perennial challenge is funding. The high costs associated with research and development and the long clinical trial process pose significant funding challenges for biotechnology companies like Rinri Therapeutics.

Scaling up the manufacturing process to produce the required number of stem cell-derived cells for later-stage clinical trials and commercialisation is a crucial challenge but a critical hurdle to overcome to realise the potential of these kinds of therapies. However, there are significant commercial opportunities from the market’s sheer scale and unmet need. The global market for hearing loss treatments is substantial, estimated at $39 billion in 2022. As there are currently no effective treatments for many types of hearing loss, Rinri Therapeutics’ therapies have market-disrupting potential and would become the first-choice regenerative hearing loss therapy worldwide.

What are the future trends for your products/processes?

The field of regenerative medicine is undergoing rapid advancements, with new discoveries and technologies emerging at an accelerated pace, bringing the promise of this therapeutic class closer to reality. Rinri Therapeutics is well-positioned to succeed in developing a therapy for hearing loss, as they are now at the forefront of this rapidly evolving field and have established a strong track record of innovation combined with preclinical and clinical progress.

The successful development and commercialisation of Rinri Therapeutics’ stem cell therapy could have a profound impact on the lives of millions of individuals around the world who are affected by hearing loss. The therapy could completely revolutionise the treatment of this prevalent condition and significantly enhance the quality of life for many people around the world.


More news and updates 

CEO Update - 20 February 2024

I'm looking forward to the BIA Committee Summit this week. It will be great to see 200 members in Westminster at one of the most lively and insightful events we do each year. I know it's the volunteer expert army that gives the BIA its unique impact with government and it's always great to understand the committee's priorities and the ideas at the intersection between committees that arise from the event.

Beyond health: why BIA is championing the biorevolution 

The BIA has named this frontier of science Deep Biotech. Our brand-new report, "Deep Biotech: Disruptive innovation for global sustainability" highlights how deep biotech is key to creating a sustainable UK bioeconomy and making the UK a science superpower that benefits all. 

Recent decision from the EPO smooths the way to obtaining patents in Europe

The BIA’s Intellectual Property Advisory Committee (IPAC) helps BIA understand and shape the environment for IP ownership to ensure strong protection for BIA member companies. Our EU policy subcommittee has taken a look at what a recent European decision means for the right to claim priority to an earlier filed patent application. This blog sets out some of the details of the case, and the practical implications for BIA members.​​​​​​​

CEO Update - 12 February 2024

It was great to see the hugely positive response we’ve had to the launch of our new report "Deep Biotech: Disruptive innovation for global sustainability". I believe we're on the cusp of a biorevolution powered by Deep Biotech, and I want our Association at the forefront of shaping the future of Deep Biotech and championing its disruptive potential.

Enter the dragon: Exploring China’s life sciences market

Next week, Chinese people across the world will be celebrating Chinese New Year. This is the “year of the dragon”, a symbol of strength for the Chinese people. It also represents prosperity, a value Chinese strive for across aspects of life, society and business.

#NAW2024: Will Smith on his Process Development Apprenticeship

I started my apprenticeship in 2020 with Gyroscope therapeutics as a process development apprentice where I worked in a small team developing a process for the production and purification of recombinant adeno-associated viruses (rAAV) to treat dry AMD.

#NAW2024: Will Crisp's journey through Level 5 Laboratory Technician Apprenticeship

I have recently finished a level 5 laboratory technician apprenticeship, while working as an apprentice at Gyroscope Therapeutics. I am 22 and started the apprenticeship after finishing my A levels.

#NAW2024: Hélène Trottin's journey through MBA apprenticeship

"The apprenticeship helped me open my mind about the extent of career possibilities in our industry and beyond. It made me more confident about my own capabilities, and how these could be of benefit to both my career and my organisation."

CEO Update - 5 February 2024

Fantastic news that new BIA Board member Ros Deegan, CEO of OMass Therapeutics has been appointed by the Prime Minister to serve on his prestigious Business Council alongside some of the biggest names from across UK business. Read on for Labour’s plan for the life sciences sector and our latest award.

#NAW2024: Role of the Institute for Apprenticeships and Technical Education

This National Apprenticeship Week (5-11 February 2024), Dr Kate Barclay, BIA's Skills Strategy Consultant, delves into the key phases of this transformation and unveils the exciting role of the Institute for Apprenticeships and Technical Education (IfATE) in working with employers to shape skills training for our future workforce. 


More within